Early treatment of chronic hepatitis B in children: Everything to play for?

Bertoletti, Antonio; Gill, Upkar S.; Kennedy, Patrick

doi:10.1016/j.jhep.2019.12.007

Cited by 1 publication

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept of early treatment for infantile hepatitis B has been reported in recent years and has proven efficacy[ 9 - 11 ]. For infantile hepatitis B, published studies mainly involve LAM therapy.…”

Section: Discussionmentioning

confidence: 99%

“…In 2019, a study by Zhu et al [ 15 ] showed early antiviral therapy with LAM (4 mg/kg, daily) contributed to the rapid negative conversion of serum HBsAg in infants under 1 year old with HBV DNA > 10 5 IU/mL and ALT more than two times the upper limit of normal. Bertoletti et al [ 9 ], however, offered a different perspective. They suggested that early antiviral therapy had no role in patients' ALT levels and that the clinical endpoints of the study should not be limited to “obtaining a higher serum HBsAg conversion rate”.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Successful treatment of infantile hepatitis B with lamivudine: A case report

Zhang¹,

Liu²,

Pan³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND How to treat infantile hepatitis B virus (HBV) infection remains a controversial issue. The nucleoside analogue lamivudine (LAM) has been approved to treat children (2 to 17 years old) with chronic hepatitis B. Here, we aimed to investigate the benefit of LAM treatment in infantile hepatitis B. CASE SUMMARY A 4-mo-old infant born to a hepatitis B surface antigen (HBsAg)-positive woman was found to be infected by HBV during a health checkup. Liver chemistry and HBV seromarker tests showed alanine aminotransferase of 106 U/L, HBsAg of 685.2 cut-off index, hepatitis B “e” antigen of 1454.0 cut-off index, and HBV DNA of > 1.0 × 10 9 IU/mL. LAM treatment (20 mg/d) was initiated, and after 19 mo, serum HBsAg was entirely cleared and hepatitis B surface antibody was present. The patient received LAM treatment for 2 years in total and has been followed for 3 years. During this period, serum hepatitis B surface antibody has been persistently positive, and serum HBV DNA was undetectable. CONCLUSION Early treatment of infantile hepatitis B with LAM could be safe and effective.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%